A Phase 3 interventional study of pitavastatin and simvastatin in Hypercholesterolemia, Dyslipidemia and Coronary Heart Disease, sponsored by Kowa Research Europe. Completed at 28 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-02.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 13th largest by enrollment, is one of 3 that started in 2006, is one of 9 in phase 3, and was the 8th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2006.
This study's enrollment of 178 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
11 studies in Hypercholesterolemia by Kowa Company, Ltd.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Hypercholesterolemia by Kowa Company, Ltd., this one is the 8th largest by enrollment, is one of 3 that started in 2006, is one of 10 in phase 3, and was the 7th registered.
Kowa Company, Ltd.’s Hypercholesterolemia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kowa Company, Ltd.’s 11 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a sixteen-week follow-on and 28 week single-blind extension study for patients who participated in study NK-104-304.
This is a sixteen-week, double-blind, active controlled, follow-on and 28 week single blind extension study for patients who participated in NK-104-304.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pitavastatin 4 mg once daily
Drug: pitavastatin
Simvastatin 40 mg or 80 mg once daily
Drug: simvastatin
Number of Patients Attaining NCEP LDL-C Target at Week 16
Number of patients attaining the National Cholesterol Education Program (NCEP) LDL-C target at Week 16. According to NCEP criteria the target LDL-C is 100 mg/dL.
Time frame: 16 weeks
Number of Patients Attaining NCEP LDL-C Target at Week 44
Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at Week 44. According to NCEP criteria the target LDL-C is 100 mg/dL.
Time frame: 44 Weeks
Percent Change From Baseline in LDL-C
Time frame: Baseline to 44 weeks
Patients with primary hypercholesterolemia or combined dyslipidemia, who have satisfied the inclusion/exclusion criteria of the core study, and completed the core study were eligible for this study.
| Milestone | Pitavastatin 4 mg | Simvastatin 40mg/80mg |
|---|---|---|
| Started | 121 | 57 |
| Completed | 109 | 47 |
| Not completed | 12 | 10 |
Number of patients attaining the National Cholesterol Education Program (NCEP) LDL-C target at Week 16. According to NCEP criteria the target LDL-C is 100 mg/dL.
| particpants | Pitavastatin 4 mg | Simvastatin 40mg/80mg |
|---|---|---|
| Number of Patients Attaining NCEP LDL-C Target at Week 16 | 98 | 45 |
Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at Week 44. According to NCEP criteria the target LDL-C is 100 mg/dL.
| Participants | Pitavastatin 4 mg | Simvastatin 40mg/80mg |
|---|---|---|
| Number of Patients Attaining NCEP LDL-C Target at Week 44 | 94 | 42 |
| percent change | Pitavastatin 4 mg | Simvastatin 40mg/80mg |
|---|---|---|
| Percent Change From Baseline in LDL-C | -41.81 ± 15.130 | -41.37 ± 16.425 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 4 mg | — | 4/121 (3.3%) | 57/121 (47.1%) |
| Simvastatin 40mg/80mg | — | 7/57 (12.3%) | 38/57 (66.7%) |
| Event | Pitavastatin 4 mg | Simvastatin 40mg/80mg |
|---|---|---|
| Angina pectorisCardiac disorders | 0/121 | 1/57 |
| Myocardial infarctionCardiac disorders | 0/121 | 1/57 |
| GastroenteritisInfections and infestations | 0/121 | 1/57 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/121 | 1/57 |
| Global amnesiaNervous system disorders | 0/121 | 1/57 |
| Transient ischaemic attackNervous system disorders | 0/121 | 1/57 |
| Urinary bladder polypRenal and urinary disorders | 0/121 | 1/57 |
| Myocardial ischaemiaCardiac disorders | 1/121 | 0/57 |
| CataractEye disorders | 1/121 | 0/57 |
| Non-cardiac chest painGeneral disorders | 1/121 | 0/57 |
| Event | Pitavastatin 4 mg | Simvastatin 40mg/80mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 24/121 | 15/57 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/121 | 7/57 |
| HeadacheNervous system disorders | 2/121 | 5/57 |
| Back painMusculoskeletal and connective tissue disorders | 10/121 | 3/57 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/121 | 4/57 |
| InfluenzaInfections and infestations | 7/121 | 3/57 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 6/121 | 1/57 |
| Age, Categorical(Participants) | Pitavastatin 4 mg | Simvastatin 40mg/80mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 98 | 44 | 142 |
| >=65 years | 23 | 13 | 36 |
| Age Continuous(years) | Pitavastatin 4 mg | Simvastatin 40mg/80mg | Total |
|---|---|---|---|
| Mean | 60.4 ± 5.80 | 60.8 ± 6.52 | 60.5 ± 6.02 |
| Sex: Female, Male(Participants) | Pitavastatin 4 mg | Simvastatin 40mg/80mg | Total |
|---|---|---|---|
| Female | 39 | 18 | 57 |
| Male | 82 | 39 | 121 |
The record gives a start of Jun 2006, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin